Related Experiment Video
Updated: Oct 19, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Crimean-Congo Hemorrhagic Fever Beyond Ribavirin: A Systematic Review
Stephanie P Fabara1, Juan Fernando Ortiz2,3, Derrick Wayne Smith4
1Internal Medicine, Universidad Catolica de Santiago de Guayaquil, Guayaquil, ECU.
Insights
Crimean-Congo hemorrhagic fever (CCHF) treatments show promise. Plasma exchange and immunoglobulins reduced mortality, while ribavirin aids post-exposure prophylaxis for this severe tick-borne illness.
Area of Science:
- Virology
- Infectious Diseases
- Public Health
Background:
- Crimean-Congo hemorrhagic fever (CCHF) is a severe tick-borne viral illness.
- It is endemic across Africa, the Mediterranean, and the Balkans.
- CCHF has a high case fatality rate, necessitating effective treatments.
Purpose of the Study:
- To review current literature on treatment and prophylactic measures for CCHF.
- To identify effective interventions for managing CCHF outbreaks.
Main Methods:
- Systematic literature search using PubMed and Medical Subject Headings (MeSH).
- Inclusion of full-text, human studies in English.
- Analysis of reported treatment outcomes and prophylactic efficacy.
Main Results:
- Plasma exchange was associated with reduced CCHF mortality.
- Immunoglobulin therapy effectively decreased disease severity and mortality risk.
- Ribavirin demonstrated utility as a post-exposure prophylaxis, with no significant route difference.
Conclusions:
- Supportive care combined with antiviral agents forms the current CCHF management cornerstone.
- Further research is crucial for definitive therapeutic agents and treatment guidelines.
- Rising CCHF outbreaks underscore the urgent need for advanced interventions.
Abstract:
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne virus endemic to a vast geographical area spanning from Africa to the shores of the Mediterranean Sea and north to the Balkans. The infection carries a high case fatality rate, which prompts the development of new treatment and prophylactic measures. This review explores the different treatment and prophylactic measures found in recent literature. For this purpose, we used Medical Subject Headings (MeSH) as well as PubMed advanced search. The inclusion criteria included full-text studies conducted on humans and in the English language. We found that plasma exchange was associated with a decrease in mortality rates. Similarly, the use of immunoglobulins proved effective in decreasing the severity and mortality risk. Ribavirin use was determined as a post-exposure prophylaxis drug with no statistically significant difference in oral or intravenous routes of administration. More studies should be conducted on CCHF as the number of outbreaks and endemic areas seem to be on the rise. For the time being, supportive therapy along with adjuvant antivirals appear to be the main course of management of CCHF. However, the need for definitive therapeutic agents and guidelines is warranted.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Venous Thrombosis III: Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Subviral Agents

